Log in

NASDAQ:DNLI - Denali Therapeutics Stock Price, Forecast & News

$17.44
+1.43 (+8.93 %)
(As of 04/3/2020 01:13 AM ET)
Today's Range
$15.72
Now: $17.44
$17.48
50-Day Range
$14.20
MA: $20.02
$26.21
52-Week Range
$12.39
Now: $17.44
$30.41
Volume378,867 shs
Average Volume757,298 shs
Market Capitalization$1.84 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.8
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease. It is also developing receptor interacting serine/threonine protein kinase 1 (RIPK1) product candidates, such as DNL747, a selective and brain-penetrant small molecule RIPK1 inhibitor product candidate that is in Phase 1b clinical trial for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). In addition, the company develops enzyme transport vehicle: iduronate 2-sulfatase, an enzyme replacement therapy program for MPS II, a lysosomal storage disorder; antibody transport vehicle (ATV): alpha-synuclein (aSyn) program, a protein that spreads throughout the brain in Parkinson's disease; ATV: triggering receptor expressed in myeloid cells 2, a therapeutic candidate designed to rescue microglial function in Alzheimer's disease; and ATV: Tau, a therapeutic targeting the spreading of Tau. Further, it is developing LF1, an undisclosed large molecule program to treat neurodegenerative diseases. Additionally, the company has various seed programs under the research, discovery, and preclinical stages of development. Denali Therapeutics Inc. has collaboration agreement with Takeda Pharmaceutical Company and Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is based in South San Francisco, California.
Read More
Denali Therapeutics logo

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DNLI
CUSIPN/A
Phone650-866-8548

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$26.68 million
Book Value$4.11 per share

Profitability

Net Income$-197,610,000.00
Net Margins-740.74%

Miscellaneous

Employees179
Market Cap$1.84 billion
Next Earnings Date5/13/2020 (Estimated)
OptionableOptionable

Receive DNLI News and Ratings via Email

Sign-up to receive the latest news and ratings for DNLI and its competitors with MarketBeat's FREE daily newsletter.


Denali Therapeutics (NASDAQ:DNLI) Frequently Asked Questions

How has Denali Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Denali Therapeutics' stock was trading at $16.88 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, DNLI stock has increased by 3.3% and is now trading at $17.44. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Denali Therapeutics?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Denali Therapeutics in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Denali Therapeutics.

When is Denali Therapeutics' next earnings date?

Denali Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, May 13th 2020. View our earnings forecast for Denali Therapeutics.

How were Denali Therapeutics' earnings last quarter?

Denali Therapeutics Inc (NASDAQ:DNLI) announced its earnings results on Thursday, February, 27th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.02. The business had revenue of $4.67 million for the quarter, compared to analysts' expectations of $15.71 million. Denali Therapeutics had a negative return on equity of 43.31% and a negative net margin of 740.74%. View Denali Therapeutics' earnings history.

What price target have analysts set for DNLI?

10 analysts have issued 12 month target prices for Denali Therapeutics' stock. Their forecasts range from $20.00 to $37.00. On average, they anticipate Denali Therapeutics' stock price to reach $29.67 in the next twelve months. This suggests a possible upside of 70.1% from the stock's current price. View analysts' price targets for Denali Therapeutics.

What are Wall Street analysts saying about Denali Therapeutics stock?

Here are some recent quotes from research analysts about Denali Therapeutics stock:
  • 1. According to Zacks Investment Research, "Denali Therapeutics Inc. is a biotechnology company. It focused on the discovery and development of therapies for patients with neurodegenerative disease, including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and others. Denali Therapeutics Inc. is based in SOUTH SAN FRANCISCO, United States. " (4/2/2020)
  • 2. HC Wainwright analysts commented, "We include in our valuation given their clinical stage, and view DNL310 as a free call option at this point. Our 12-month price target of $28/share is based on an equally weighted composite of (a) $29/share, as a 35x multiple of taxed and diluted FY34 GAAP EPS of $8.62 discounted back to and (b) an NPV of $28/ share (discount rate 12.0%, growth rate 2.5%). The assumptions are in-line with the expected PE multiple and discount rate of an early development-stage biopharmaceutial company." (8/8/2019)

Has Denali Therapeutics been receiving favorable news coverage?

News coverage about DNLI stock has been trending very negative on Thursday, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Denali Therapeutics earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news aboutDenali Therapeutics.

Are investors shorting Denali Therapeutics?

Denali Therapeutics saw a decline in short interest in the month of March. As of March 13th, there was short interest totaling 9,469,800 shares, a decline of 8.4% from the February 27th total of 10,340,000 shares. Based on an average daily volume of 637,600 shares, the days-to-cover ratio is currently 14.9 days. Approximately 13.2% of the company's shares are short sold. View Denali Therapeutics' Current Options Chain.

Who are some of Denali Therapeutics' key competitors?

What other stocks do shareholders of Denali Therapeutics own?

Who are Denali Therapeutics' key executives?

Denali Therapeutics' management team includes the following people:
  • Dr. Ryan J. Watts Ph.D., Co-Founder, Pres, CEO, Chief Scientific Officer & Director (Age 43)
  • Mr. Alexander O. Schuth M.D., Co-Founder, COO & Sec. (Age 46)
  • Dr. Marc Tessier-Lavigne, Co-Founder, Chairman of Scientific Advisory Board & Director (Age 59)
  • Mr. Steve E. Krognes, CFO & Treasurer (Age 50)
  • Dr. Carole Ho, Chief Medical Officer & Head of Devel. (Age 46)

When did Denali Therapeutics IPO?

(DNLI) raised $149 million in an initial public offering on Friday, December 8th 2017. The company issued 8,300,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs, Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Evercore ISI was co-manager.

What is Denali Therapeutics' stock symbol?

Denali Therapeutics trades on the NASDAQ under the ticker symbol "DNLI."

How do I buy shares of Denali Therapeutics?

Shares of DNLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Denali Therapeutics' stock price today?

One share of DNLI stock can currently be purchased for approximately $17.44.

How big of a company is Denali Therapeutics?

Denali Therapeutics has a market capitalization of $1.84 billion and generates $26.68 million in revenue each year. The company earns $-197,610,000.00 in net income (profit) each year or ($2.07) on an earnings per share basis. Denali Therapeutics employs 179 workers across the globe. View additional information about Denali Therapeutics.

What is Denali Therapeutics' official website?

The official website for Denali Therapeutics is http://www.denalitherapeutics.com/.

How can I contact Denali Therapeutics?

Denali Therapeutics' mailing address is 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-866-8548.


MarketBeat Community Rating for Denali Therapeutics (NASDAQ DNLI)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  363 (Vote Outperform)
Underperform Votes:  381 (Vote Underperform)
Total Votes:  744
MarketBeat's community ratings are surveys of what our community members think about Denali Therapeutics and other stocks. Vote "Outperform" if you believe DNLI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DNLI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel